Company Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Country | IL |
IPO Date | Jul 27, 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 79 |
CEO | Philip A. Serlin CPA, M.B.A., CPA, MBA |
Contact Details
Address: Modi’in Technology Park Hevel Modi'in, IL | |
Website | https://www.biolinerx.com |
Stock Details
Ticker Symbol | BLRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001498403 |
CUSIP Number | 09071M205 |
ISIN Number | US09071M2052 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer |
Mali Zeevi CPA, CPA | Chief Financial Officer |
Dr. Ella Sorani Ph.D. | Chief Development Officer |
Holly W. May M.B.A. | President of BioLineRx USA |
John Lacey | Head of Corporate Communications & Investor Relations |
Raziel Fried | Treasurer & Budgetary Control Director |
Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 25, 2024 | 6-K | Filing |
Nov 21, 2024 | 6-K | Filing |
Nov 21, 2024 | 424B5 | Filing |
Nov 12, 2024 | 6-K | Filing |
Nov 05, 2024 | 6-K | Filing |
Oct 16, 2024 | 6-K | Filing |
Oct 01, 2024 | 6-K | Filing |
Aug 19, 2024 | 6-K | Filing |
Aug 15, 2024 | 6-K | Filing |
Jun 18, 2024 | 6-K | Filing |